You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Hims
since
auto-detected in 26 stories
3 days ago
These are the stocks posting the largest moves in early trading.
8 days ago
Stocks making the biggest moves premarket: Walmart, Hims & Hers, Carvana, Figma & more ○
These are the stocks posting the largest moves in the premarket.
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion ⊕
found
The deal would give Hims & Hers a foothold in Australia and Japan while deepening its presence in the United Kingdom, Germany, and Canada.
17 days ago
Wegovy maker sues rival over 'knock-off' weight-loss drugs ⊖
Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".
18 days ago
Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more ○
These are the stocks posting the largest moves in premarket trading.
Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill ⊕
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
20 days ago
US signals crackdown on compounded weight-loss drugs; Hims shares tumble ⊕
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.
US announces crackdown on copycat weight-loss drugs ○
found
a story from Financial Times ✅ › Financial Times
Food and Drug Administration targets Hims & Hers after telehealth company undercuts Novo Nordisk on obesity shot
21 days ago
Novo Nordisk says it will take legal action after Hims & Hers reveals $49 copy of Wegovy pill ○
Hims said it would sell a copy of the newly launched weight loss pill for $49, far less than the $149 Novo sells the branded pill for.
3 months ago
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq ⊕
Oddity is branching into medical skincare with a new telehealth platform Methodiq, which blends the retailer's investments into biotech and computer vision.